10,000+ stock pitches from top investors available on joinyellowbrick.com
BAKER BROS. ADVISORS LP 13F Holdings
Holdings from the most recent 13F from BAKER BROS. ADVISORS LP
Filed: 2025-02-14 (Q4 2024) | Holdings: 95 | Value: $9.4B | Filing Link
PREMIUM
Author Returns
Returns are calculated from when the filing is published and are weighted by the size of the holding.
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Filing Returns
Returns are calculated from when the filing is published and are weighted by the size of the holding.
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Holding Returns | |||||||
|---|---|---|---|---|---|---|---|
| Stock | Put/Call | Change | Holding Pct | Value | Current Return | 3M Return | 1Y Return |
| INCY - Incyte Corporation | 22.68% | $2.1B | -8.17% | -11.24% | |||
| ONC - BeiGene, Ltd. | Reduce 10% $(191.5M) | 18.81% | $1.8B | +0.17% | -5.93% | ||
| ACAD - ACADIA Pharmaceuticals Inc. | 8.40% | $786.8M | +10.10% | -12.00% | |||
| MDGL - Madrigal Pharmaceuticals, Inc. | 6.51% | $609.3M | -19.67% | -13.46% | |||
| SMMT - Summit Therapeutics Inc. | 4.66% | $435.9M | +21.00% | +7.30% | |||
| RVMD - Revolution Medicines, Inc. | Add 5% ($16.1M) | 3.71% | $347.2M | -7.37% | -3.17% | ||
| INSM - Insmed Incorporated | Add 13% ($40.8M) | 3.69% | $345.7M | -16.87% | -15.79% | ||
| RYTM - Rhythm Pharmaceuticals, Inc. | Reduce 5% $(17.6M) | 3.64% | $340.6M | +5.30% | +6.34% | ||
| KYMR - Kymera Therapeutics, Inc. | 2.58% | $241.2M | -23.18% | -19.93% | |||
| KOD - Kodiak Sciences Inc. | 1.84% | $172.2M | -33.21% | -36.45% | |||
| EWTX - Edgewise Therapeutics, Inc. | Add 5% ($8.4M) | 1.76% | $164.4M | -45.39% | -43.60% | ||
| BCYC - Bicycle Therapeutics plc | Add 16% ($20.8M) | 1.63% | $152.4M | -35.18% | -35.81% | ||
| REPL - Replimune Group, Inc. | 1.43% | $133.8M | -40.04% | -48.58% | |||
| ALKS - Alkermes plc | 1.28% | $120.3M | -16.74% | -13.09% | |||
| N/A - Insmed Incorporated | 0.99% | $92.9M | |||||
| TRDA - Entrada Therapeutics, Inc. | 0.90% | $84.1M | -42.57% | -39.99% | |||
| ABCL - AbCellera Biologics Inc. | 0.86% | $80.7M | -40.35% | -40.94% | |||
| DNLI - Denali Therapeutics Inc. | 0.81% | $76.1M | -39.41% | -34.20% | |||
| NRIX - Nurix Therapeutics, Inc. | 0.78% | $73.1M | -43.31% | -46.58% | |||
| ARGX - argenx SE | 0.74% | $68.8M | -9.88% | -12.15% | |||
| RARE - Ultragenyx Pharmaceutical Inc. | 0.71% | $66.3M | -19.80% | -18.66% | |||
| KNSA - Kiniksa Pharmaceuticals International, plc | 0.60% | $55.7M | +38.38% | +31.32% | |||
| IMTX - Immatics N.V. | Add 13% ($5.9M) | 0.55% | $51.7M | +1.18% | -7.68% | ||
| CRSP - CRISPR Therapeutics AG | Add 55% ($18.3M) | 0.55% | $51.5M | -28.75% | -30.50% | ||
| STOK - Stoke Therapeutics, Inc. | Add 6% ($2.9M) | 0.55% | $51.1M | -12.69% | -10.83% | ||
| IMCR - Immunocore Holdings plc | 0.48% | $44.7M | +4.10% | -3.93% | |||
| ROIV - Roivant Sciences Ltd. | Add 35% ($11.5M) | 0.48% | $44.6M | +0.57% | +1.89% | ||
| SERA - Sera Prognostics, Inc. | 0.47% | $44.2M | -59.06% | -40.82% | |||
| IMVT - Immunovant, Inc. | Add 39% ($12.0M) | 0.45% | $42.3M | -30.88% | -31.76% | ||
| XENE - Xenon Pharmaceuticals Inc. | 0.42% | $39.0M | -26.80% | -24.02% | |||
| CELC - Celcuity Inc. | Add 43% ($10.5M) | 0.37% | $35.1M | -18.67% | -18.51% | ||
| GLUE - Monte Rosa Therapeutics, Inc. | 0.36% | $34.1M | -41.07% | -43.83% | |||
| AKRO - Akero Therapeutics, Inc. | 0.33% | $30.5M | -11.81% | -22.24% | |||
| CERS - Cerus Corporation | 0.32% | $30.0M | -33.42% | -32.11% | |||
| N/A - Ionis Pharmaceuticals, Inc. | New Purchase | 0.32% | $29.5M | ||||
| GRAL - GRAIL, Inc. | New Purchase | 0.31% | $29.1M | -28.43% | -32.09% | ||
| IDYA - IDEAYA Biosciences, Inc. | 0.29% | $27.3M | -6.86% | -17.57% | |||
| KRYS - Krystal Biotech, Inc. | 0.28% | $26.6M | -19.34% | -14.78% | |||
| CADL - Candel Therapeutics, Inc. | New Purchase | 0.28% | $25.9M | -37.14% | -45.93% | ||
| PRAX - Praxis Precision Medicines, Inc. | Add 3% ($648.6K) | 0.27% | $25.5M | -59.21% | -59.02% | ||
| IGMS - IGM Biosciences, Inc. | 0.27% | $25.0M | -13.29% | -19.58% | |||
| CNTA - Centessa Pharmaceuticals plc | 0.22% | $20.6M | -24.14% | -26.24% | |||
| MRUS - Merus N.V. | Add 50% ($6.3M) | 0.20% | $18.9M | +23.09% | -1.35% | ||
| DYN - Dyne Therapeutics, Inc. | 0.17% | $15.8M | -16.54% | -16.68% | |||
| NGNE - Neurogene Inc. | Add 48% ($5.0M) | 0.16% | $15.4M | -4.13% | +5.16% | ||
| XNCR - Xencor, Inc. | 0.16% | $15.4M | -53.94% | -49.97% | |||
| BCAX - Bicara Therapeutics Inc. | 0.16% | $14.5M | -30.34% | +6.55% | |||
| PRLD - Prelude Therapeutics Inc. | 0.14% | $12.9M | -12.19% | -5.43% | |||
| IONS - Ionis Pharmaceuticals, Inc. | New Purchase | 0.13% | $12.5M | +3.84% | +5.64% | ||
| ALMS - Alumis Inc. | 0.13% | $12.3M | -25.24% | +1.52% | |||
| BMEA - Biomea Fusion, Inc. | Reduce 100% | 0.00% | $0.00 | ||||
| NMRA - Neumora Therapeutics, Inc. | Reduce 100% | 0.00% | $0.00 | ||||
| TCRX - TScan Therapeutics, Inc. | Reduce 100% | 0.00% | $0.00 | ||||
| TSVT - 2seventy bio, Inc. | Reduce 100% | 0.00% | $0.00 | ||||